Chinese expert consensus on the management of chimeric antigen receptor T cell therapy-associated coagulopathy  

作　　者：Heng Mei Fangping Chen Yue Han Ming Hou He Huang Xiaojun Huang Yuhua Li Aibin Liang Qifa Liu Ting Niu Jun Peng Wenbin Qian Yongping Song Jianxiang Wang Ying Wang Depei Wu Kailin Xu Linhua Yang Renchi Yang Lei Zhang Liansheng Zhang Xi Zhang Xiaohui Zhang Weili Zhao Weidong Han Yu Hu 

机构地区：[1]Department of Hematology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,Hubei 430022,China [2]Department of Hematology,Xiangya Third Hospital,Central South University,Changsha,Hunan 410013,China [3]Jiangsu Institute of Hematology,National Clinical Research Center for Hematologic Diseases,The First Affiliated Hospital of Soochow University,Suzhou,Jiangsu 215006,China [4]Department of Hematology,Qilu Hospital,Cheeloo College of Medicine,Shandong University,Jinan,Shandong 250063,China [5]Institute of Hematology,The First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou,Zhejiang 310003,China [6]Peking University People’s Hospital,Peking University Institute of Hematology,Beijing 100044,China [7]Department of Hematology,Zhujiang Hospital,Southern Medical University,Guangzhou,Guangdong 510282,China [8]Department of Hematology,Tongji Hospital of Tongji University,Shanghai 200092,China [9]Department of Hematology,Nanfang Hospital,Southern Medical University,Guangzhou,Guangdong 510515,China [10]Department of Hematology,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,China [11]Department of Hematology,The Second Affiliated Hospital,College of Medicine,Zhejiang University,Hangzhou,Zhejiang 310009,China [12]Affiliated Cancer Hospital of Zhengzhou University,Zhengzhou,Henan 450008,China [13]State Key Laboratory of Experimental Hematology and National Clinical Research Center for Blood Disease,Institute of Hematology and Blood Diseases Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Tianjin 300020,China [14]Department of Hematology,The Affiliated Hospital of Xuzhou Medical University,Xuzhou,Jiangsu 221006,China [15]Department of Hematology,The Second Hospital of Shanxi Medical University,Taiyuan,Shanxi 030001,China [16]Department of Hematology,Lanzhou University Second Hospital,Lanzhou,Gansu 730030,China [17]Medical Center of Hematology,Xinqiao Hospital,The Third Military Medical University,Chongqing 400037,China [18]

出　　处：《Chinese Medical Journal》2022年第14期1639-1641,共3页中华医学杂志（英文版）

摘　　要：Chimeric antigen receptor T-cell(CAR-T)therapy has greatly improved the disease remission rate and long-term survival rate of patients with relapsed/refractory hematological malignancies.[1-3]Currently,several commercial CAR-T products are available in the market and numerous CAR-T clinical trials have been conducted.Attention should be paid to the safety of CAR-T therapy.The main adverse effects of CAR-T therapy are cytokine release syndrome(CRS)and immune effector cell-associated neurotoxicity syndrome(ICANS).[4]

关 键 词：CLINICAL CYTOKINE release 

分 类 号：R55[医药卫生—血液循环系统疾病]